Press release

The 10 INSTEX shareholder states have decided to liquidate INSTEX due to continued obstruction from Iran: E3 statement

The governments of the UK, France and Germany (the 'E3') gave a joint statement announcing the liquidation of INSTEX.

This was published under the 2022 to 2024 Sunak Conservative government

The governments of the UK, France and Germany (E3) statement:

The INSTEX shareholders – Belgium, Denmark, Finland, France, Germany, the Netherlands, Norway, Spain, Sweden, and the UK – have decided to liquidate INSTEX.

INSTEX was set up by France, Germany, and the United Kingdom in 2019 to facilitate legitimate trade between Europe and Iran, particularly in humanitarian goods. Over the past 4 years, INSTEX has consistently tried to facilitate trade exchanges between Europe and Iran. There was a strong and sustained demand by European exporters to use the INSTEX mechanism, mainly from the humanitarian sector.

For political reasons, Iran has systematically prevented INSTEX from fulfilling its mandate. Iran only agreed to a single transaction, in early 2020, for the export of medical goods from Europe to Iran. After that, Iran consistently and deliberately blocked other proposals for transactions between the United Kingdom, Norway, the European Union and Iran. This was born from a political determination to impede the use of INSTEX under any circumstance. Thus, the Iranian leadership has chosen to act against the interests of its people by refusing to cooperate on the export of medicine and other life-saving goods.

In light of Iran’s persistent refusal to engage with the company, the INSTEX shareholders have reached the conclusion that there is no more ground for maintaining INSTEX operational. The INSTEX shareholders have voted in favour of the dissolution of INSTEX at the extraordinary general assembly of 9 March 2023. This decision is taken on its own merits for exclusively commercial reasons.

Media enquiries

Email [email protected]

Telephone 020 7008 3100

Contact the FCDO Communication Team via email (monitored 24 hours a day) in the first instance, and we will respond as soon as possible.

Updates to this page

Published 9 March 2023